PHIO PHARMACEUTICALS CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
PHIO PHARMACEUTICALS CORP. (PHIO) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 113.74% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2025-03-31
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2019-03-31 was 98.87%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-09-30 was 161.45%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-06-30 was 95.77%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2016-09-30 was 116.88%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 113.74%, a 0.00% change from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 113.74%.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2013 was 76.36%, a 13.91% decline from fiscal 2012.
- PHIO PHARMACEUTICALS CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2012 was 88.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2024-12-31 | 113.74% 10-K · filed 2025-03-31 | |||
| 2023-12-31 | 113.74% 10-K · filed 2024-04-01 | |||
| 2019-03-31 | 98.87% 10-Q · filed 2019-05-14 | |||
| 2018-09-30 | 161.45% 10-Q · filed 2018-11-14 | |||
| 2018-06-30 | 95.77% 10-Q · filed 2018-08-14 | |||
| 2016-09-30 | 116.88% 10-Q · filed 2016-11-10 | |||
| 2014-09-30 | 103.47% 10-Q · filed 2015-11-12 | |||
| 2013-12-31 | 76.36% 10-K · filed 2014-03-28 | |||
| 2013-09-30 | 107.30% 10-Q · filed 2014-11-13 | 76.27% 10-Q · filed 2013-11-14 | ||
| 2013-06-30 | 75.53% 10-Q · filed 2013-08-14 | 75.53% 10-Q · filed 2013-08-14 | ||
| 2012-12-31 | 88.70% 10-K · filed 2014-03-28 | |||
| 2012-09-30 | 115.20% 10-Q · filed 2013-11-14 | 88.70% 10-Q · filed 2013-11-14 | ||
| 2012-06-30 | 88.38% 10-Q · filed 2013-08-14 | 88.38% 10-Q · filed 2013-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |